If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

“That’s not Pfizer,” Bourla said on an investor call in January regarding Abrysvo’s commercial performance. GSK has asked the FDA to expand approval for Arexvy for adults aged 50 to 5 ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK’s chief commercial officer ... Zhifei also gets the right of first refusal to be the exclusive partner for Arexvy, which is not yet approved in China, but has been cleared in the US ...

Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...

GSK’s Arexvy had an exceptional launch and generated ... Per the terms of the alliance, Sanofi is the commercial lead and AstraZeneca is the development and manufacturing lead.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual ...

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...

The updated COVID-19 vaccines are officially available at U.S. pharmacies across the country. Here are other vaccines recommended for adults.

Experts hope this year’s rollout will be smoother than last year's, which was the first time the COVID-19 vaccine was managed by commercial ... adults this season: Arexvy from GSK, Abrysvo ...